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Abstract
Background: CD164 (also known as MGC-24v or endolyn) is a sialomucin which has been suggested to participate
in regulating the proliferation, cell adhesion and differentiation of hematopoietic stem and progenitor cells. CD164
is also involved in the development of cancer. The functions of cis-regulatory elements of CD164 remain relatively
unknown.
Methods: In this study, we investigated the function of cis-regulatory elements within the promoter of CD164. We
fused the 5’-flanking region of CD164 to a luciferase reporter vector. The minimal promoter region was confirmed
by luciferase reporter assay. Using in silico analysis, we found the presence of one HIF-1alpha (HIF-1A) motif (5_-
RCGTG-3_) overlapping E-box (CACGTG) and two AP-1-like binding sites (CGCTGTCCC, GTCTGTTG), one of which is
also overlapped with HIF-1alpha sequence. Dual-luciferase assay was performed to examine the transcriptional
activity of AP-1 and HIF-1alpha of CD164 promoter. Quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR) was performed to measure CD164 expression. Chromatin Immunoprecipitation was used to confirm the
binding of HIF-1alpha and CD164.
Results: Co-transfection of c-jun, HIF-1alpha and minimal promoter region construct demonstrated that c-jun and
HIF-1alpha bound the CD164 promoter and promoted CD164 expression. Hypoxia treatment also led to the up-
regulation of CD164 expression. The mutation of overlapping sequences resulted in the reduced expression of
CD164 induced by HIF-1alpha. Chromatin Immunoprecipitation demonstrated that the HIF-1alpha bound the
minimal promoter region.
Conclusions: Determination of the optimal promoter region and transcription factors governing CD164 expression
is useful in understanding CD164 functions. These results suggest that cis-regulatory elements of CD164
overlapping HIF-1alpha/E-box/AP-1-like sequences may play important regulatory roles.
Background
CD164 (MGC-24v or endolyn) is a member of the sialo-
mucin family, a mucin containing sialic acid, which is
highly conserved in humans and other species [1-4].
The human CD164 gene is located on chromosome
6q21 [2,4-6]. CD164 was first identified on CD34
+
human hematopoietic progenitor cells and bone marrow
stromal reticular cells [2,6,7]. CD164 has been
implicated in adhesion, proliferation and differentiation
of hematopoietic stem and progenitor cells [6,8]. CD164
was suggested to mediate the adhesion of CD34
+ hae-
matopoietic progenitor cells to bone marrow stromal
cells and SDF-1-induced binding to bone marrow
endothelial cells [2,9,10]. CD164 is thought to regulate
hematopoiesis by facilitating the adhesion of human
CD34+ cells to bone marrow stroma [5]. Knocking
down CD164 expression in Drosophila S2 cells
increased the cell apoptosis rate [1]. CD164 also partici-
pated in the localization of prostate cancer cells to the
bone marrow and has been identified new markers for
acute lymphoblastic leukaemia [11,12]. Previous work
also confirmed the roles of CD164 on the development
of colorectal cancer [13]. CD164 gene expression is
regulated by specific transcription factors which bind to
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entiation. Our attention has recently turned to an inves-
tigation of the cis-regulatory elements of CD164.
Determining the optimal promoter region and transcrip-
tion factors governing CD164 expression is important in
understanding CD164 functions.
In the present study, we proceeded to identify CD164
promoter and performed the functional analysis of cis-
regulatory element on CD164 expression.
Methods
1. Prediction of promoter
Promoter 2.0 Prediction Server was employed for pre-
diction of promoter. As CD164 first exon begins on
10418(AL359711 CD164 gDNA), ATGtcgcggc, the 3192
bp sequence 5’ upstream of TSS were analyzed by the
this method.
2. Construction of plasmids
Human c-jun expression plasmid pCMV-2/c-jun, which
contains the full-length coding region of human c-jun
cDNA cloned in pCMV-2 vector and pCMV-2 empty
vector, were gifts from Dr. Gavin P. Collett (Department
of Surgery, The Cancer Centre, Queen’sU n i v e r s i t yB e l -
fast, UK). Vector plasmids pCDNA3.1-HIF-1A(1-826)
and pCDNA3.1 were kindly donated by Dr. Zhou
(Department of Orthopaedics and Traumatology, The
University of Hong Kong). Firefly luciferase reporter
plasmid pGL3-Basic was purchased from Promega. For
construction of 5’-deletions of CD164 promoter reporter
plasmids, human genomic DNA was isolated using the
FlexiGene DNA Kit (Qiagen), the CD164 promoter can-
didate fragments were amplified by polymerase chain
reaction (PCR) from genomic DNA, and PGL3P4.2-4
fragment was synthesized by two complementary strand
oligonucleotides. Fragments were cloned into the
pCR2.1-TOPO vector (Invitrogen). Cloning of different
fragments to pGL3-Basic (Promega), which is a vector
carrying the firefly luciferase gene were performed after
the restrictive enzyme cut. The restrictive endonucleases
used for the cloning are shown in Table 1. The restric-
tion endonucleases which were used predominantly
were Sac I and XholI, except P1 fragment, because of an
internal SacI site existing in fragments between P1 and
P1.5. P1 segment was obtained by using the KpnI and
XholI sites in pCR2.1-TOPO vector. Finally, all plasmids
were confirmed by sequencing. The oligonucleotides
used for PCR primers are shown in Table 1.
3. Identification and mutation of AP-1-like binding sites in
CD164 promoter
Sequence homology to the AP-1 consensus sequence
(TGACTCA) was identified using TFBIND, which is a
software programme for searching transcription factor
binding sites. Mutation of AP-1-like sites and Ebox sites
was performed by Stratagene’s QuikChange II Site
Directed Mutagenesis Kit.
Primers for distal AP-1 mutation are as follows: -
forward: 5’-CAG GGG CCT CTC ACG CTG TCC
CTG CGC GCT CCC G-3’;
reverse: 5’-CGG GAG CGC GCA GGG ACA GCG
TGA GAG GCC CCT G-3’.
Primers for proximal AP-1 mutation were as follows: -
forward: 5’-CAG GGG ATT GAG GGG TCT GTT
GAG CGT TGC GAG CCT TAG-3’;
reverse: 5’-CTA AGG CTC GCA ACG CTC AAC
AGA CCC CTC AAT CCC CTG-3’.
Primers for Ebox mutation: -
forward: 5’-CCG AAA ACA GGG GCC TCT AGA
TTG ACC CCT GCG CGC TCC CGC GGG-3’;
reverse: 5’-CCC GCG GGA GCG CGC AGG GGT
CAA TCT AGA GGC CCC TGT TTT CGG-3’;
Primers for Ebox deletion: -
Table 1 The oligonucleotides used for PCR primers
Forward Reverse Restriction sites Amplified DNA Fragment Length (bps)
P1 5’-aagcgatcctcctgcctca-3’ 5’-cgtgtcctcagcgctggcgttcg-3’ KpnI XholI 1796
P2 5’-aagcgatcctcctgcctca-3’ 5’-cgtgtcctcagcgctggcgttcg-3’ SacI XholI 1453
P3 5’-agtagatggcgctcaccttta-3’ 5’-cgtgtcctcagcgctggcgttcg-3’ SacI XholI 1024
P4 5’-gcacagtcgctttgagggcc-3’ 5’-cgtgtcctcagcgctggcgttcg-3’ SacI XholI 258
P5 5’-taggattcccgttggtatcg-3’ 5’-cgtgtcctcagcgctggcgttcg-3’ SacI XholI 197
P6 5’-gaaaacaggggcctctcac-3’ 5’-cgtgtcctcagcgctggcgttcg-3’ SacI XholI 139
P7 5’-cgggggagcgtagtctcg-3’ 5’-cgtgtcctcagcgctggcgttcg-3’ SacI XholI 100
P8 5’-cgaaaacaggggcctc
tcacgtgacccctgcgcgctccc
gcgggggagcgtagtctcg-3’
5’-cgagactacgctccccc
gcgggagcgcgcaggggtca
cgtgagaggcccctgttttcg-3’
SacI XholI 39
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Page 2 of 10forward: 5’-GCA CGC CGA AAA CAG GGG CCT
CTA CCC CTG CGC GCT CCC GCG GGG-3’;
reverse: 5’-CCC CGC GGG AGC GCG CAG GGG
TAG AGG CCC CTG TTT TCG GCG TGC-3’.
4. Luciferase activity assay
Firefly (Photinus pyralis) luciferase is widely used as a
reporter of promoter activities by cloning interested
promoters to the upstream of the firefly luciferase cod-
ing gene. Nowadays, the dual-reporter assays, where
the activities of firefly and Renilla (Renilla reniformis,
also known as sea pansy) luciferases are measured
sequentially from a single sample, are commonly used
to improve experimental accuracy. The activity of the
experimental reporter (firefly) is normalized by the
activity of the internal control (Renilla). Cells were
transfected with constructed reporter vectors simulta-
neously with phRL vector (Promega) containing cDNA
coding Renilla luciferase; 2 ng of the latter was applied
to each well in a 24-well plate. 48 hrs after transfec-
tion, cells were harvested with passive Lysis buffer, a
component of the Dual-Luciferase Reporter (DLR™)
Assay System (Promega), according to the manufac-
turer’s instructions. An appropriate volume of cell
lysate was added to a well of the F96 MicroWell™
Plates (NUNC, Roskilde, Denmark), followed by 25 μl
of LARII. Firefly luciferase activities were measured
with a luminometer (Tecan, Theale, UK). Renilla luci-
ferase activities were also measured. Relative luciferase
activity was represented by the ratio of firefly luciferase
activity to renilla luciferase activity. Each experimental
group included 3 repeats and data were shown as
means.
5. Cell culture
In this work, HCT116 cells (cell line catalogues:
ECACC 91091005) were exclusively used to study the
role of CD164 in cancer development. All the cell lines
were obtained from the European Collection of Cell
Cultures (ECACC) and cultured in a CO2 incubator
(Sanyo
®). HCT116 and HT29 cell lines were cultured
in DMEM and SW480, K562 in RPMI-1640 medium
supplemented with penicillin G (100 U/mL; Sigma
®),
streptomycin (100 mg/mL; Sigma
®) and 10% fetal calf
serum (Gibco
®). Cells were grown at 37°C in a humidi-
fied atmosphere of 5% CO2 and were routinely sub-
cultured using 0.25% (w/v) trypsin-EDTA solution. For
testing promoters’ activity under hypoxia, cells were
transiently transfected with pGL3P4 plasmids and cul-
tured in DMEM without serum for 24 hours; then the
cells were transferred into an Invivo2 400™ Hypoxia
workstation (Ruskinn Technology Ltd) for different
time courses.
6. Western blot
Protein used for western blotting was extracted with
mRIPA buffer containing protease inhibitors (mRIPA,
50 mM Tris, pH 7.4, 100 mM NaCl, 1% Nonidet P-40,
0.5% deoxycholic acid, 0.1% SDS, Aprotinin 10 μg/ml,
Leupeptin 10 μg/ml, PMSF 1 mM). Proteins were quan-
tified using BCA
TM Protein Assay Kit (Pierce, Northum-
berland, UK). The Western Blot system was set up
using a Biorad Bis-Tris Gel system, according to the
manufacturer’s instructions (Biorad, Hertfordshire, UK).
Rabbit-anti-human HIF-1alpha antibody (Millipore) was
prepared in 3% blocking buffer at a dilution of 1:1000.
The primary antibody was incubated with the mem-
brane at 4ºC overnight followed by a brief wash and
incubation with secondary antibody for 1 hour at room
temperature. Finally, peroxide and luminol solutions 1:1
(Pierce, UK) were added to cover the blot surface for
five minutes at room temperature and the membrane
was placed in a developing cassette.
7. Chromatin precipitation
Chromatin immunoprecipitation (ChIP) assay was per-
formed using the Chromatin Immunoprecipitation
Assay kit (EZ ChIP, Millipore) according to the manu-
facturer’s instructions. Briefly, HCT116 cells were trans-
fected with pCDNA3.1-HIF-1A. Forty-eight hours after
transfection, the cells were then cross-linked by 1% for-
maldehyde for 10 min. The formaldehyde was quenched
using 2 M glycine for 5 min. at room temperature
before harvest. Cells were collected by centrifuging in
PBS containing protease inhibitors and were lysed in
SDS-lysis buffer. Soluble chromatin was prepared after
sonication to an average DNA length of 200 to 1000 bp.
Fragmented chromatin was immunoprecipitated over-
night at 4°C on a rotating platform, using antibodies
against HIF-1alpha (Millipore) together with Protein A/
G Plus-Agarose. The agarose beads were washed, chro-
matin extracted and protein-DNA cross-links reversed.
DNA was purified and was analyzed by PCR using the
specific primers (5’-GCACAGTCGCTTTGAGGGCC-3’;
5’-CGTGTCCTCAGCGCTGGCGTTCG-3’). Normal
immunoglobulin G (IgG) was used as a negative control.
Anti-RNA Polymerase II was used as positive control.
The total input was the supernatant from the no-anti-
body control.
8. Quantitative real-time polymerase chain reaction (qRT-
PCR)
The total RNAs were isolated from cells with Trizol
®
reagent (Invitrogen) and possible genomic DNA con-
tamination were eliminated by treatment with RNase-
free DNase 1 (Sigma) for 1 hr. The extracted RNAs
were immediately reverse-transcribed using the
SMART
TM MMLV RT Reverse Transcriptase CDNA
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iQ™5 Multicolor Real-Time PCR detection System
(Bio-Rad) using the following specific primers: -
CD164 (5’-GTGCTGTCCGCGGACAAGAAC-3’;5 ’-
TGTGAACAATAGCTCTCATC-3’);
GAPDH (5’-CGAGATCCCTCCAAAATCAA-3’;5 ’-
GGTGCTAAGCAGTTGGTGGT-3’).
The PCR primer pairs were designed with Primer3
software. Primer specificity has been validated by
BLAST analysis. Real-time PCR was performed using
SYBR Green Master Mix (an asymmetrical cyanine dye
by Promega) with Mg2+ concentration 6 mM, template
cDNA and 0.5 μm of each primer, with RNA-negative
and water controls. The qPCR cycle was 98°C for 2
min., 40 cycles of 95°C for 15 sec., 60°C for 30 sec. Final
melt-curve analysis (60°-95°C) was included. The stan-
dard curve was produced with slopes at approximately
-3.32 (~100% efficiency); PCR quantification used ΔΔct
method for the CD164 against the GAPDH for normali-
zation. The data are representative of the means of
three experiments.
Results
Identification of CD164 promoter
Promoter 2.0 Prediction Server [14] was employed for
predicting the CD164 promoter region. Promoter 2.0
predicts transcription start sites of vertebrate PolII pro-
moters in DNA sequences. It can also be used to predict
transcription factors that bind to the sequences in pro-
moter regions, based on the theorems that are common
to neural networks and genetic algorithms (http://www.
cbs.dtu.dk/services/Promoter/). As first exon of the
CD164 gene begins on 10418 [GenBank: AL359711],
atgtcgcggc, a 3192 bp sequence at the 5’ upstream of
the transcription start site (TSS) was analyzed by Pro-
moter 2.0 Prediction. The sequence of the putative pro-
moter region of the gene is embedded at position -800
bp upstream of the TSS (Table 2). To determine the
minimal promoter region, the 1.7 kb genomic sequence
was subcloned in pGL3 basic upstream of the luciferase
reporter gene. These 5’-deleted constructs pGL3 P1
(-1796/1), pGL3 P2(-1153/1), pGL3 P3(-1024/1), pGL3
P4(-258/1), pGL3 P5 (-197/1), pGL3 P6(-139/1), pGL3 7
(-135/-96) and pGL3 8(-100/1) were transfected to
HCT116, as shown in Figure 1B. The primers amplifying
the corresponding fragments were as shown in Methods.
Renilla luciferase was used for normalization of firefly
luciferase expression. The highest activity appeared in
P3, in which the length of promoter is from -1024
upstream of the TSS (Figure 1B). P4 showed a lower
level of activation than P3. However, balancing their
length, P4 was recognized as the minimal promoter
region for the CD164 gene (Figure 1C). Deletion of the
region from P3 to P6 resulted in a 75% reduction in
basal promoter activity. These data suggested the exis-
tence of a minimal promoter region within the sequence
-258/1. P3 activity was analyzed in different cell lines
including K562, HCT116, HT29 and SW480, of which
HCT116 showed the highest P4 activity (Figure 1D).
In silico prediction of minimal promoter regions
The putative minimal promoter regions P4 (-258
upstream of the TSS) were analyzed with TFBIND
(http://tfbind.hgc.jp/), a software program for searching
transcription factor binding sites [15]. The P4 sequence
contains two AP-1-like binding sites which are located
at -119 bps (A, distal) and -54 bps (B, proximal)
upstream of the TSS, respectively (Figure 2B). The
results are shown in Table 3.
Effects of C-Jun and HIF-1alpha on the P4 minimal
promoter activity
C-Jun is a proto-oncogene. Its expression has been stu-
died in many tumour types [16]. C-Jun, in combination
with c-FOS, forms the AP-1 early response transcription
factor. In order to determine the effect of the potential
effects of C-Jun on minimal promoter P4 activity, we
co-transfected HCT116 cells and SW480 cells with
pCMV-c-jun or pCMV-2 empty vector and reporter
vector pGL3 P4(-258/1). The C-Jun was able to increase
the minimal promoter activity by about 50% in both cell
lines (Figure 2A). The upregulation of CD164 by C-Jun
at mRNA level was observed using real-time PCR (Fig-
ure 2A). To investigate whether the AP-1-like motifs
play roles in CD164 gene expression, the wild-type
pGL3 P4 construct or its mutants (P4AP-1 Amu, P4AP-
1B m u ,P 4 A P - 1Both mu pGL3 constructs) as shown in
Figure 2B, were transfected into HCT116 cells. In
HCT116 cells, the activities of P4AP-1 Amu and P4AP-
1, Both mu mutants, were reduced by about 40% com-
pared to pGL3P4 wild-type (Figure 2B). In contrast,
there was no significant change of activity in P4AP-1
Bmu (p > 0.05 Student’s t-test) compared to pGL3P4
wild-type. Significant difference (p < 0.05 Student’st -
test) between P4AP-1 Amu and P4AP-1 Bmu showed
the location of different responses to endogenous tran-
scription factors. The distal AP-1-like motif which
Table 2 Prediction of the CD164 promoter using
Promoter 2.0 Prediction Server
Position Score Likelihood
800 1.107 Highly likely prediction
2100 0.607 Marginal prediction
2800 0.588 Marginal prediction
The sequence of the putative promoter region of the gene is embedded at
position -800 bp upstream of TSS
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promoter was essential for CD164 transcription. The
responses of AP-1-like motif to exogenous C-Jun were
tested by co-transfected pCMV-C-Jun construct and the
mutants. The mutants, especially P4AP-1 Amu and
P4AP-1 Both mu, resulted in decreased activities com-
pared to the wild-type. Thesed a t as u g g e s t e dt h a tt h e
AP-1-like motif is one of the main elements in the
CD164 gene promoter. P4AP-1 Bmu, after treatment
with exogenous C-Jun showed significantly different
promoter activity, compared to the control. It seemed
that AP-1-like site in -54 (proximal) was more sensitive
to exogenous C-Jun than endogenous stimulatory
factors.
TFBIND also identified several other transcription fac-
tors which contain putative binding sites for transcrip-
tion factors, several of which exactly match or are very
s i m i l a rt ot h o s ea l r e a d yk n o w n ,l i k et h eA P - 1 - l i k es i t e s
described above. It also revealed the presence of one
HIF-1alpha motif (5_-RCGTG-3_) overlapping E-box
(CACGTG) and distal AP-1-like binding sites (Figure
3A). To investigate the contribution of this E-box to the
activity of the P4 region, constructs with mutation the
E-box in the promoter region were subcloned into the
pGL3-basic plasmids and used to transfect the HCT116
cells. For the normalized luciferase activity, a significant
decrease of luciferase activity was found in the P4 con-
taining E-box mutation compared to the HCT116 cells
Figure 1 Analysis of the 5’-flanking region of CD164 gene promoter. (A) The PCR products of a series of 5’-deleted mutants of the CD164
gene promoter were subcloned to a pGL3 Luciferase reporter system at the SacI/XholI site, except P1.0 which used a KpnI/XhloI site to generate
the CD164 promoter-pGL3 expression plasmid. (B) The 5’-deleted constructs were transfected into HCT116 cells with lipofectamine 2000. 48
hours after transfection, their luciferase activities were examined as described in Methods. Basic pGL3 plasmid without promoter was used as a
control. Luciferase activity was normalized to the activity of renilla which were co-transfected as an internal control. The numbers represented
the sites 5’-upstream of TSS. Deletion of the region from P2 to P3.2 resulted in a 75% reduction in basal promoter activity. The data bars
represented the mean values of three experiments, each performed in triplicate. The error bars represented the standard errors. (C) Relative
promoter’s activity against promoter’s length. P4 showed the optimal activity according to its length. These data suggested the existence of a
minimal promoter region within the sequence. (D) Cell-type specificity of CD164 promoter activity. P4 activity was analyzed in different cell lines
including K562, HCT116, HT29 and SW480. HCT116 cells showed the highest P4 activity.
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Page 5 of 10Figure 2 Effects of c-jun expression on the transcriptional activation of CD164 promoter. (A) SW480 and HCT116 cells were transiently co-
transfected with the pGL3P4 (0.8 μg/μl) and pCMV-c-jun (0.8 μg/μl), luciferase activity of cell lysates was measured and normalized to renilla
activity as internal control (left). Results represented the mean ± SD of three independent experiments. Exogenous c-jun significantly enhanced
the CD164 expression, *p < 0.01, Student’s t-test. The Real-time PCR were performed to investigate the upregulated expression CD164 at mRNA
level in HCT116 (right). (B) Mutational analysis of AP-1-like sites on CD164 promoter fragment P4. Schematic representation of the pGL3P4
regions containing AP-1-like binding sequence and its mutants. pGL3P4, a wild-type construct containing 258 bps of the 5’-flanking sequence
upstream of TSS; P4AP-1 Amu, a mutated pGL3P4 plasmid containing a mutated AP-1-like motif (CGCTGTCCC) at -119; P4AP-1 Bmu, a mutated
pGL3P4 plasmid containing a mutated AP-1-like motif (GTCTGTTG) at -54; P4AP-1 Both mu, a mutated pGL3P4 plasmid containing two mutated
AP-1-like motifs (CGCTGTCCC,GTCTGTTG) at both of -119 and -54. pGL3P4 and its mutants were transfected in HCT 116 cells respectively and
assayed for luciferase activity The relative activities of wild-type P4 and AP-1-like mutated P4 mutants were normalized with renilla expression.
P4AP-1 Amu and P4AP-1 Both mu resulted in significant decreases in luciferase activity when compared to pGL3P4, whereas no significant
change of luciferase activity was observed in P4AP-1 Bmu.
Table 3 Prediction of AP-1-like transcription factor binding sites on the P4 promoter
Access ID Score Location Strand Consensus Sequence Signal Sequence
M00174 V$AP1_Q6 0.818353 -119 (+) NNTGACTCANN CGTGACCCCTG
M00174 V$AP1_Q6 0.863106 -54 (+) NNTGACTCANN GTTGACTGAGC
AP-1-like binding sites (distal and proximal) were found
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Page 6 of 10transfected with wild-type P4 (p < 0.001, student T-Test,
Figure 3B). To determine whether HIF-1alpha mediates
the increased activity of pGL3P4 in HCT116 cells, co-
transfection of a HIF-1alpha plasmid with pGL3P4 was
performed. Co-transfection of a HIF-1alpha expressing
plasmid with pGL3P4 resulted in a significant increase
in the promoter activity (p < 0.01, Student’st - t e s t ,F i g -
ure 3B). To investigate the effect of HIF-1alpha through
HIF-1alpha/E-box overlapping sequence, the pcDNA3.1-
HIF-1alpha was co-transfection with PGL3P4 containing
E-box mutation. For the normalized luciferase activity, a
significant decrease of luciferase activity was found in
the co-transfection with PGL3P4 containing E-box
mutation compared to the HCT116 cells co-transfected
with wild-type PGL3P4 (p < 0.001, student T-Test, Fig-
u r e3 B ) .I td e m o n s t r a t e dt h a tH I F - 1 a l p h a / E - b o x / A P - 1 -
like sequences is crucial cis-regulatory elements of
CD164 expression.
Hypoxia exists in the microenvironment of solid
tumours and stem cells. In the present study, in vitro
hypoxia treatment was carried out to examine if hypoxia
mediates CD164 expression. The promoter activity was
determined under hypoxic conditions and pGL3P4 plas-
mids were transiently transfected into the HCT116 cells.
The cells were cultured in DMEM without serum for 24
hours, then transferred into gas-exchange chambers
maintained at 37°C with 1% pO2.
Figure 4A shows that, compared to normal oxygen con-
ditions, 2 hours of treatment of hypoxic conditions appear
to depress pGL3P4 activity, although there is no significant
difference. At 8 hours of hypoxic treatment, the activity of
pGL3P4 was significantly higher than that of the normal
oxygen level group (p < 0.05 Student’s t-test). The upregu-
lation of CD164 by HIF-1alpha at mRNA level was
observed using real-time PCR (Figure 4C). The result sug-
gested that hypoxia might be one of the factors upregulat-
ing CD164 gene expression in HCT116 cells. HIF-1alpha
levels were therefore tested using western blot in the
experiments described above. Figure 4B shows that HIF-
1alpha protein expression was increased in a time-depen-
dent manner in the hypoxic chamber.
Binding of HIF-1alpha to PGL3P4 minimal promoter
sequence
In order to confirm the binding of HIF-1alpha to the
promoter of CD164, Chromatin immunoprecipitation
(ChIP) assay was performed. We transfected HIF-1alpha
plasmid to the HCT116 cells. The anti-HIF-1alpha was
used to precipitate protein/chromatin complexes from
sonicated samples. The complexes were then processed
to DNA amplification. As shown in Figure 4D, it
demonstrated the binding of HIF-1alpha to the minimal
region of promoter of CD164.
Discussion
A cis-regulatory element is a region of DNA or RNA
near a gene required for proper spatiotemporal expres-
sion of that gene, often containing binding sites for
transcription factors. The mechanisms by which CD164
expression is activated have been defined in this study.
The different lengths of 5’-deleted mutant constructs of
the CD164 showed different luciferase activities. The
luciferase activities reached their peak in P2 which was
1024 bps upstream of the transcription star site and was
70-fold greater than that of the control group. The luci-
ferase activity assays also indicated that the CD164 pro-
moter had relative cell specificity, as its ability to
activate luciferase was different in HCT116, K562, HT29
and SW480 cells. The PGL3P4 promoter had a proximal
region of approximate 258 bases that increased the pro-
moter activity by more than 50-fold and was recognized
as the most effective promoter when compared to their
sizes.
From the in silico analysis, the overlapping HIF-
1alpha/E-box/AP-1-like sequences was found in the
minimal region of CD164 promoter. C-jun and hypoxia
upregulated the expression of CD164. Mutation of the
overlapping sites resulted in reduced expression of
CD164. Two AP-1-like sites (distal site and proximal
site) on this proximal promoter region, of which distal
site located in the overlapping sites, were identified by
the in silico analysis. The consensus AP-1 (activator pro-
tein 1) recognition sequence is TGACTCA but many
variations of this sequence (AP-1-like sites) were found
in the promoter regions of target genes, including tyro-
sine hydroxylase [17], prodynorphin [18], proenkephalin
[19] and glial fibrillary acidic protein [20]. Two putative
AP-1-like sites in the CD164 gene PGL3P4 segment
were found in the present study by bioinformatic ana-
lyses. The AP-1 transcription factor is a dimeric com-
plex, and correlates with multi-stage tumor
development, including tumor cell proliferation [21,22];
apoptosis [23,24]; tumor invasion and angiogenesis
[25,26]. The main AP-1 proteins in mammalian cells are
Jun and FOS. Endogenous and exogenous transcription
factors influence the CD164 expression by binding to
AP-1-like sites. In the condition without exogenous fac-
tors, the distal AP-1-like site, located at -119, which was
supposed to bind endogenous factors including c-jun,
may play a major role, as mutation of this site induced a
40% decrease of CD164 basal expression in HCT116
cells, whereas no significant effect was found by mutat-
ing the proximal AP-1-like site. Therefore, the distal
AP-1-like site which is overlapped with HIF-1alpha/E-
BOX sequence plays a more important role than the
proximal AP-1-like site, which is located at -54 for
endogenous factors. However, the proximal AP-1-like
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Page 7 of 10Figure 3 The functions of overlapping E-box, HIF-1alpha and AP-1-like sequences within CD164 P4 promoter.( A )S c h e m a t i c
presentation of the Overlapping HIF-1A/E-box/AP-1-like in the minimal promoter region of CD164. (B) Mutation analysis of the putative E-box on
CD164 promoter P4 region. Constructs with mutation of the E-box in the promoter region were subcloned into the pGL3-basic plasmid and the
HCT116 cells were transfected. Significant decrease of luciferase activity was found in the E-box mutation P4 mutant (p < 0.001, Student’s t-test).
Co-transfection of a HIF-1alpha expressing plasmid with pGL3P4 resulted in a significant increase in the promoter activity (p < 0.01, Student’st -
test). To investigate the effect of HIF-1alpha through HIF-1alpha/E-box overlapping sequence, the pcDNA3.1- HIF-1alpha was co-transfection with
PGL3P4 containing E-box mutation. For the normalized luciferase activity, a significant decrease of luciferase activity was found in the co-
transfection with PGL3P4 containing E-box mutation compared to the HCT116 cells co-transfected with wild-type PGL3P4 (p < 0.001, student T-
Test).
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Page 8 of 10site was sensitive to exogenous c-jun It is likely that the
CD164 expression in HCT116 cells is also controlled by
both exogenous and endogenous factors through AP-1-
like sites. CD164 may be a target gene in the AP-1 path-
way and plays crucial roles in tumor development.
A number of studies have suggested that normal stem
cells reside in “niches,” which support and maintain the
undifferentiated phenotype of the stem cells. These
niches may be hypoxic and hypoxia may play roles in
maintaining the stem cell phenotype. Under hypoxia,
HIFs regulate a variety of pro-angiogenic and pro-glyco-
lysis pathways. In solid cancers, regions of hypoxia are
commonly present throughout the tissue. In this study,
hypoxia treatment and the transfection of HIF-1alpha
induced the expression of CD164. Our results and pre-
vious studies showed that eight hours of treatment in a
hypoxia chamber resulted in the highest level of HIF-
1alpha expression. The ChIP showed the binding of
HIF-1alpha to the promoter of CD164. It demonstrated
that the hypoxic treatment upregulated the expression
of CD164 through HIF-1alpha binding the promoter of
CD164.
Conclusions
In conclusion, the results presented here have confirmed
cis-Regulatory functions of overlapping HIF-1alpha/E-
box/AP-1-like sequences of minimal promoter region of
CD164. The research performed in this paper represents
Figure 4 Effects of hypoxia on CD164 expression. (A) Hypoxia increased activity of CD164 promoter. HCT 116 cells were transfected with
pGL3P4 plasmids and treated in hypoxia chamber. The normalized luciferase activities were shown. After 8 hours, the activity of pGL3P4 in
hypoxia group was significantly higher than that of normal group (p < 0.05 student’s t-test). No significant difference was found at 1hr and 2hrs.
(B) HIF-1 alpha protein level was tested using western blot and there was an increase of HIF-1alpha protein expression in a time-dependent
manner. (C) Real-time PCR was performed to investigate the upregulated expression CD164 at mRNA level in HCT116 after transfection of HIF-1
a. (D) Chromatin immunoprecipitation analysis of HIF-1alpha binding to the CD164 promoter. DNA released from the precipitated complexes
was amplified by PCR. The PCR products were separated by agarose gel electrophoresis. Lane 1: IgG control; Lane 2: anti-RNA polymerase II;
Lane 3: HIF-1alpha antibody pull-down; Lane 3:Input
Tang et al. BMC Molecular Biology 2011, 12:44
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Page 9 of 10the combination of in silico biology and molecular biol-
ogy. The elucidation of the cis-regulatory elements is
useful in understanding CD164 functions in cancer cells.
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